Metabolic syndrome: Schizophrenia and atypical antipsychotics

Perspectives in Psychiatric Care

Volumn 42, Issue 3, 2006, Pages 204-207

  Keltner, Norman L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

CHEMICALLY INDUCED DISORDER; COMORBIDITY; DRUG EFFECT; EPIDEMIOLOGY; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; NURSE ATTITUDE; PATIENT EDUCATION; REVIEW; SCHIZOPHRENIA; UNITED STATES; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CAUSALITY; COMORBIDITY; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; NURSE'S ROLE; PATIENT EDUCATION; SCHIZOPHRENIA; UNITED STATES; WEIGHT GAIN;

EID: 33746894543     PISSN: 00315990     EISSN: 17446163     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2006.00073.x     Document Type: Review

References (26)

1. American Psychiatric Association. (1997). Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154(4 Suppl.), 1-63.
2. Anonymous. (2005). The prevalence and treatment of mental illness today. Harvard Mental Health Letter, 22(5), 4-6.
3. Antai-Otong, D. (2004). Metabolic effects associated with atypical antipsychotic medications. Perspectives in Psychiatric Care, 40(2), 70-72.
4. Adiseshiah, M. (2005). Effective care of patients with type 2 diabetes and dyslipidemia: A nurse's perspective. Diabetes Research & Clinical Practice, 68(Suppl. 2), S23-S27.
5. Birkenaes, A.B., & Andreassen, O.A. (2004). The metabolic side effects of antipsychotic medications. Psychiatry Review Series, 4, 4-7.
6. Brown, S., Inskip, H., & Barraclough, B. (2000). Causes of excessive mortality of schizophrenia. British Journal of Psychiatry, 177, 212-217.
7. Carmena, R. (2005). Type 2 diabetes, dyslipidemia, and vascular risk: Rationale and evidence for correcting the lipid imbalance. American Heart Journal, 150(5), 859-870.
8. Colditz, G.A., Willett, W.C., Rotnitzky, A., & Manson, J.E. (1995). Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine, 122, 481-486.
9. Dickerson, F.B., Goldberg, R.W., Brown, C.H., Kreyenbuhl, J.A., Wohlheiter, K., Fang, L., et al. (2005). Diabetes knowledge among persons with serious mental illness and type 2 diabetes. Psychosomatics, 46(5), 418-424.
10. Drake, R. (2001). Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services, 52(4), 469-476.
11. Goldman, L.S. (1999). Not just schizophrenia - many patients have coexisting medical illnesses. In Excerpta Medica, Inc. Therapeutic Advances in Psychoses (pp. 4-5). Belle Mead, NJ: Author.
12. Kannel, W.B. (2005). Risk stratification of dyslipidemia: insights from the Framingham Study. Current Medicinal Chemistry Cardiovascular & Hematological Agents, 3(3), 187-193.
13. Kawachi, I. (1999). Health consequences of weight gain. In Excerpta Medica, Inc. Therapeutic Advances in Psychoses (pp. 1-3). Belle Mead, NJ: Author.
14. Kessler, R.C., Chiu, W.T., Demler, O., & Walters, E.E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 62, 617-627.
15. Kilgore, C. (2005). Groups affirm utility of metabolic syndrome dx. Clinical Psychiatry News, 33(10), 71.
16. Mahoney, D. (2005). Mental illness prevalence high, despite advances. Clinical Psychiatry News, 33(7), 1, 8.
17. Newcomer, J.W., Haupt, D.W., Fucetola, R., Melson, A.K., Schweiger, J.A., Cooper, B.P., et al. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry, 59(4), 337-345.
18. Osby, U., Correia, N., Brandt, L., Ekbom, A., & Sparen, P. (2002). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research, 45(1-2), 21-28.
19. Petty, R. (2003). Diabetes in schizophrenia. Tucker, GA: The Promedica Research Center.
20. Ryan, M.C., & Thakore, J.H. (2002). Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Science, 71(3), 249-257.
21. Sernyak, M.J., Leslie, D.L., Alarcon, R.D., Losonczy, M.F., & Rosenheck, R. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159, 561-566.
22. Sherman, C. (2005a). Schizophrenia-bipolar I theory gains traction. Clinical Psychiatry News, 33(9), 27.
23. Sherman, C. (2005b). Vicious circle of comorbidity links medical, mental illness. Clinical Psychiatry News, 33(10), 66.
24. Straker, D., Correll, C.U., Kramer-Ginsburg, E., Abdulhamid, N., Koshy, F., Rubens, E., et al. (2005). Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. American Journal of Psychiatry, 162(6), 1217-1221.
25. Weiden, P.J., & McEvoy, J.P. (2005). Medical risk factors in patients with serious psychiatric disorders. Clinical Psychiatry News, Suppl 3, 1-4.
26. World Health Organization. (1999). Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Geneva: Author. Retrieved March 11, 2006, from http://www.who/ncd/ncs 99.2